Accueil   Diary - News   All news Theranexus and its partners receive support from the French Inter‐ministry Fund for their project, Cx‐COG

Theranexus and its partners receive support from the French Inter‐ministry Fund for their project, Cx‐COG

logo-theranexusTheranexus, a clinical‐stage biopharmaceutical company, has announced today that it has received funding from the FUI (French Inter‐ministry Fund) for its project CX‐COG (FUI AAP22) which hasbeen approved by the competitiveness clusters Lyonbiopôle and Atlanpôle Biothérapies.

 

 

This project, which will be carried out in collaboration with the team of Prof. Régis Bordet (Lille University, Lille University Hospital, Inserm) and the company Synerlab, concerns the pharmaceutical formulation development and clinical validation of the efficacy of product THN201 in the treatment of neurocognitive impairment particularly associated with Alzheimer’s disease.

 

 

Read the press release